Management Insights for Optimizing
in the Treatment of Hemophilia
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from February
20, 2018 to February 28, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Bayer HealthCare Pharmaceuticals and Shire
Hemophilia is an inherited disorder caused by a defect in one of the
X chromosomes resulting in excessive bleeding and easy bruising.
Bleeding can be external or internal and bleeding into the joints is
likely to cause long term damage if not treated quickly. In
addition, bleeding in the brain is an even more serious problem for
those with severe hemophilia as it can be caused by a simple head
bump. While females are typically carriers of the genetic defect,
the majority of cases are seen in males and it’s believed that 1 in
5,000 males are born with hemophilia every year. Hemophilia A is
more common than B and each type require different treatments.
Hemophilia is diagnosed through blood tests to determine the
severity of the disease and discover which clotting factor is low or
missing. Replacement therapy remains the mainstay of treatment which
contain concentrates of clotting factor and is can be synthetic or
made with human blood. Early treatment and prophylactic therapy is
critical to effectively managing the disease and improving patient
outcomes by preventing joint damage. Patient education is also
critical as infusions can be taught to patients and done at home,
alleviating unnecessary doctor appointments and lowering the cost of
treatment. Demand therapy is less expensive however there is a risk
that the delay in treatment can cause damage to joints and muscles.
Another possibility for replacement therapy is having a vein access
device implanted, which makes access easier. However, these devices
can get infected and need proper care. Thankfully new and emerging
treatments are becoming available and include longer lasting agents
that cut down the number of infusions needed per year. These options
have the potential to increase patient compliance while decreasing
the possibility of inhibitors forming.
Upon Completion of this
activity, participants will be able to:
Analyze clinical data and updated
treatment guidelines evaluating current and emerging hemophilia
prophylaxis therapies to ensure optimal management
Review the most recent clinical
strategies for monitoring and managing inhibitors in patients
Identify the barriers of
pharmacokinetic studies and coagulation assays in optimizing
therapy for patients with hemophilia
Apply increased knowledge regarding
the strategies, tools and scales to screen for, prevent, and
Explore appropriate strategies for
improving adherence among patients with hemophilia through
education and collaboration between caregivers and healthcare
||Mark T. Reding, MD
Associate Professor of Medicine
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
acts as an advisor or consultant for Bayer HealthCare,
Bioverativ, Genentech, Novo Nordisk and Shire. He also
serves as a speaker or a member of a speaker’s bureau
for Bioverativ and Shire. He has received grants for
clinical research from Bayer HealthCare. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by educational grants from
Bayer HealthCare Pharmaceuticals and Shire
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue